Paris, France — 25 January 2023 at 08:00 am CET —Lysogene (FR0013233475 – LYS), a phase…
Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…
Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…
Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…
Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…
Paris, France – 31 March 2022 at 8:00 am CET – Lysogene (FR0013233475 – LYS),…
Topline data of the main cohort of AAVance clinical trial expected in Q3 2022Stabilization or…
New positive biomarker data from 16 patients treated with LYS-SAF302 showing reduction in heparan sulfate…
Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…
Cash and cash equivalents of €12.3 million[1] as of 31 December 2021 Paris, France —…